GSK, after consumer spinoff, touts momentum for core products Cabenuva and Shingrix

With GSK’s consumer healthcare spinoff now in the rearview mirror, the company is operating as the lean, innovative medicines-focused drugmaker CEO Emma Walmsley envisioned years ago (PDF).

And 2022’s financial performance shows the company’s promise as it seeks to grow sales by at least 5% annually through 2026.